• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=21642991).
  

PubMed=21356356; DOI=10.1016/j.ajpath.2010.12.014; PMCID=PMC3070574
Fabien Gueugnon, Sabrina Leclercq, Christophe Blanquart, Christine Sagan, Laurent Cellerin, Martine Padieu, Christian Perigaud, Arnaud Scherpereel, Marc Gregoire;
Identification of novel markers for the diagnosis of malignant pleural mesothelioma.
Am. J. Pathol. 178:1033-1042(2011)

PubMed=21540305; DOI=10.1183/09031936.00160210
David Roulois, Virginie Vignard, Fabien Gueugnon, Nathalie Labarriere, Marc Gregoire, Jean-Francois Fonteneau;
Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells.
Eur. Respir. J. 38:1117-1126(2011)

PubMed=21642991; DOI=10.1038/ng.855; PMCID=PMC4643098
Matthew J. Bott, Marie Brevet, Barry Stephen Taylor, Shigeki Shimizu, Tatsuo Ito, Lu Wang, Jenette Creaney, Richard A. Lake, Maureen F. Zakowski, Boris A. Reva, Chris Sander ...Show all 18 authors... , Robert Delsite, Simon N. Powell, Qin Zhou, Rong-Lai Shen, Adam B. Olshen, Valerie W. Rusch, Marc Ladanyi; Show fewer authors
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Nat. Genet. 43:668-672(2011)

PubMed=21774103; DOI=10.1097/JTO.0b013e318215a07d
Marie Brevet, Shigeki Shimizu, Matthew J. Bott, Neerav Shukla, Qin Zhou, Adam B. Olshen, Valerie W. Rusch, Marc Ladanyi;
Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
J. Thorac. Oncol. 6:864-874(2011)

PubMed=26539644; DOI=10.18632/oncotarget.6285; PMCID=PMC4792599
Carole Achard, Nicolas Boisgerault, Tiphaine Delaunay, David Roulois, Steven Nedellec, Pierre-Joseph Royer, Mallory Pain, Chantal Combredet, Mariana Mesel-Lemoine, Laurent Cellerin, Antoine Magnan ...Show all 14 authors... , Frederic Tangy, Marc Gregoire, Jean-Francois Fonteneau; Show fewer authors
Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
Oncotarget 6:44892-44904(2015)